Written on Tuesday 16th May 2017
The Fungal Service Evaluation Tool (FSET) was developed and funded by Merck Sharp & Dohme Limited and is provided as a service to medicine pursuant to Clause 19 of the ABPI code of practice.
The Fungal Service Evaluation Tool (FSET) has been developed as a service to medicine to support UK NHS Trusts in the management of haematological patients at risk of invasive fungal infections through the evaluation of selected antifungal prophylaxis agents.
pH Associates (an OPEN Health company) and Harvey Walsh (an OPEN Health company) worked closely with MSD and several NHS users to develop a web based tool only available on the NHS N3 server that can be used to provide information to hospitals in real time regarding patient outcomes, prophylactic agents used, prevalence of breakthrough invasive fungal infections and resource use associated with antifungal prophylaxis and treatment of breakthrough invasive fungal infections.
The FSET was a shortlisted finalist in the 'Joint Working' category at the recent PHARMAfield Awards in March, and was highly commended by the judges. #pfawards2017
For further information on the OPEN Health Real World Evidence and Patient Centred Outcomes offering please contact Sam Oliver, Joint Managing Director at pH Associates on SamOliver@phassociates.com or +44 (0)1628 481112; and for further information on the OPEN Health Healthcare Informatics offering please contact Chris Hodgson, Commercial Director at Harvey Walsh on Chris.Hodgson@harveywalsh.co.uk or 07468 714 601